Diagnosis and the premotor phase of Parkinson disease

Neurology

Volumn 72, Issue 7 SUPPL. 2, 2009, Pages

  Tolosa, Eduardo ^a,b   Gaig, Carles ^a   Santamaría, Joan ^a   Compta, Yaroslau ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL ASSESSMENT; DEPRESSION; DYSAUTONOMIA; ERECTILE DYSFUNCTION; HUMAN; HYPOSMIA; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; SMELLING DISORDER; SYMPTOM; EARLY DIAGNOSIS; GENETICS; MOOD DISORDER; PATHOPHYSIOLOGY;

EARLY DIAGNOSIS; HUMANS; MOOD DISORDERS; OLFACTION DISORDERS; PARKINSON DISEASE; PRIMARY DYSAUTONOMIAS; SLEEP DISORDERS;

EID: 61949235512     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318198db11     Document Type: Article

References (90)

1. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis J Neural Transm 1976;38:277-301.
2. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1987;45:19-34.
3. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: SN regional selectivity. Brain 1991;114:2283-2301.
4. Morrish PK, Rakshi JS, Bailey DL, et al. Measuring the rate of progression and estimating the premotoral period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
5. Marek K, Innis R, van Dyck C, et al. [123I]B-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-2094.
6. The Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-1943.
7. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351:2498-2508.
8. Gonera EG, Van't Hof M, Berger HJC, Van Weel C, Horstink MWIM. Symptoms and duration of the premotor phase in Parkinson's disease. Mov Disord 1997;12: 871-876.
9. Abbott RD, Ross GW, White LR, et al. Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J Neurol 2003;250(Suppl 3):30-39.
10. Iranzo A, Molinuevo JL, Santamaría J, et al. Rapid-eyemovement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006;5:572-577.
11. Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 2006;21:2062-2067.
12. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 2007; 22:839-842.
13. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
14. Katzenschlager R, Lees AJ. Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol 2004;17:417-423.
15. Doty RL, Stern MB, Pfeiffer C, et al. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55:138-142.
16. Stern M, Doty RL, Dotti M, et al. Olfactory function in Parkinson's disease subtypes. Neurology 1994;44:266-268.
17. Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001;16:41-46.
18. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008;63:167-173.
19. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004;19:1196-1202.
20. Stiasny-Kolster K, Doerr Y, Möller JC, et al. Combination of "idiopathic" REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005;128:126-137.
21. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006;66:845-851.
22. Markopoulou K, Larsen KW, Wszolek EK, et al. Olfactory dysfunction in familial parkinsonism. Neurology 1997;49: 1262-1267.
23. Montgomery EB, Baker KB, Lyons K, Koller WC. Abnormal performance on the PD test battery by asymptomatic first degree relatives. Neurology 1999;52:757-762.
24. Berendse HW, Booij J, Francot GMJE, et al. Subclinical dopaminergic dysfunction in symptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001;50:34-41.
25. Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a premotoral sign of Parkinson's disease. Ann Neurol 2004;56:173-181.
26. Siderowf A, Jennings D, Connolly J, Doty RL, Marek K, Stern MB. Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease. Mov Disord 2007;22:2249-2255.
27. Marras C, Goldman S, Smith A, et al. Smell identification ability in twin pairs discordant for Parkinson's disease. Mov Disord 2005;20:687-693.
28. Awerbuch GI, Sandyk R. Autonomic functions in the early stages of Parkinson's disease. Int J Neurosci 1994;74:9-16.
29. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456-462.
30. Gao X, Chen H, Schwarzschild M, et al. Erectile function and risk of Parkinson's disease. Am J Epidemiol 2007;166: 1446-1450.
31. Becker G, Müller A, Braune S, et al. Early diagnosis of Parkinson's disease. J Neurol 2002;249(Suppl 3):40-48.
32. Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 2004;111:201-216.
33. Chaudhuri KR, Daniel G, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
34. Tolosa E, Compta Y, Gaig C. The pre-motor phase of Parkinson disease. Parkinsonism Relat Disorders 2007; 13(suppl):S2-S7.
35. Edwards LL, Pfeiffer RF, Quigley EMM, Hofman R, Baluff M. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991;6:151-156.
36. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003;2:107-116.
37. Camilleri M, Bharucha AE. Gastrointestinal dysfunction in neurologic disease. Semin Neurol 1996;16:203-216.
38. McCallum RW, Brown RL. Diabetic and nondiabetic gastroparesis. Curr Treat Options Gastroenterol 1998;1:1-7.
39. Ueki A, Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol 2004;251(Suppl 7):18-23.
40. Kaye J, Gage H, Kimber A, Storey L, Trend P. Excess burden of constipation in Parkinson's disease: a pilot study. Mov Disord 2006;21:1270-1273.
41. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord 1997;12:946-951.
42. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Autonomic dysfunction in Parkinson's disease: a comprehensive symptom survey. Parkinsonism Relat Disord 2002;8:277-284.
43. Jost WH, Eckardt VF. Constipation in idiopathic Parkinson's disease. Scand J Gastroenterol 2003;38:681-686.
44. Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Characterization of swallowing and defecation in Parkinson's disease. Am J Gastroenterol 1994;89:15-25.
45. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007; 69:333-341.
46. O'Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord 2008;23:101-106.
47. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007;22:1581-1586.
48. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72.
49. Bronner G, Royter V, Korczyn AD, Giladi N. Sexual dysfunction in Parkinson's disease. J Sex Marital Ther 2004; 30:95-105.
50. O'Sullivan SS, Holton JL, Massey LA, et al. Parkinson's disease with Onuf 's nucleus involvement mimicking multiple system atrophy. J Neurol Neurosurg Psychiatry 2008; 79:232-234.
51. Bloch A, Probst A, Bissig H, Adams H, Tolnay M. Alphasynuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 2006;32: 284-295.
52. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, et al. Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders? a cohort study. Neurology 2007;68:2012-2018.
53. Goldstein DS. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 2006;16:46-54.
54. Orimo S, Uchihara T, Nakamura A, et al. Axonal alphasynuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008; 131:642-650.
55. Takatsu H, Nishida H, Matsuo H, et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 2000;41:71-77.
56. Fujishiro H, Frigerio R, Burnett M, et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord 2008;23:1085-1092.
57. Papapetropoulos S, Argyriou AA, Chroni E. No correlation between the clinical severity of autonomic symptoms (SCOPA-AUT) and electrophysiological test abnormalities in advanced Parkinson's disease. Mov Disord 2006;21: 430-431.
58. Matsui H, Nishinaka K, Oda M, Komatsu K, Kubori T, Udaka F. Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms? Parkinsonism Relat Disord 2006;12: 284-288.
59. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-189.
60. Leentjens AF. Depression in Parkinson's disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol 2004;17:120-126.
61. Robins AH. Depression in patients with Parkinsonism. Br J Psychiatry 1976;128:141-145.
62. Lieberman A. Depression in Parkinson's disease - a review. Acta Neurol Scand 2006;113:1-8.
63. Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007;69:342-347.
64. Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986;36:1130-1133.
65. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000;15:669-677.
66. Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 2001;104:380-386.
67. Nilsson FM, Kessing LV, Sorensen TM. Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatr Scand 2002;106:202-211.
68. Schurmann AG, van den Akker H, Ensinck KTJL, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002;58:1501-1504.
69. Leentjens AFG, Van den Akker M, Metsemakers JFM, et al. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003;18: 414-418.
70. Lauterbach EC, Freeman A, Vogel RL. Differential DSM-III psychiatric disorder prevalence and profiles in dystonia and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2004;16:29-36.
71. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 2006;113:211-220.
72. Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 2007;130:1799-1807.
73. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 1990;5:280-285.
74. van Hilten JJ, Weggeman EA, van der Velde GA, Kerkhof JG, van Dijk JG, Roos RAC. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm 1993;5:235-244.
75. Tandberg E, Larsen JP, Karlsen KA. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998;13:895-899.
76. Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson's disease. Mov Disord 2002;17:775-781.
77. Fabrinni G, Barbanti P, Aurilia C, Vanacore N, Pauletti C, Meco G. Excessive daytime sleepiness in de novo and treated Parkinson's disease. Mov Disord 2002;17:1026-1030.
78. Carter J, Carroll VS, Lannon MC, Vetere-Overfield B, Barker R. Sleep disruption in untreated Parkinson's disease. Neurology 1990;40(suppl 1):220.
79. Ferini-Strambi L, Franceschi M, Pinto P, Zucconi M, Smirne S. Respiration and heart rate variability during sleep in untreated Parkinson patients. Gerontology 1992; 38:92-98.
80. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleopathy. Mov Disord 2001;16:622-630.
81. Schenck C, Mahowald MW. REM sleep behaviour disorder: clinical, developmental and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep 2002;55:281-288.
82. Zarranz JJ, Fernández-Bedoya A, Lambarri I, et al. Abnormal sleep architecture is an early feature in the E46K familial synucleinopathy. Mov Disord 2005;20:1310-1315.
83. Abbot RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005;65:1442-1446.
84. Gagnon JF, Bedard MA, Fantini MD, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002;59:585-589.
85. Iranzo A, Santamaria J, Rye DB, et al. Characteristics of idiopathic REM sleep behaviour disorder and that associated with MSA and PD. Neurology 2005;65:247-252.
86. Kumru H, Santamaria J, Tolosa E, Iranzo A. Relation between subtype of Parkinson's disease and REM sleep behaviour disorder. Sleep Med 2007;8:779-783.
87. Vendette M, Gagnon JF, Décary A, et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 2007;69: 1843-1819.
88. Frucht S, Rogers MD, Greene PE, Gordon PE, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 58:1908-1910.
89. Gjerstad MD, Aarsland D, Larsen JP. Development of daytime somnolence over time in Parkinson's disease. Neurology 2002;58:1544-1546.
90. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol 2008;34:284-295.